Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coli surface antigen 6 (CS6) is a critical colonization factor and surface protein expressed by Enterotoxigenic Escherichia coli (ETEC), most notably the prototype human challenge strain B7A (O148:H28). As a non-fimbrial adhesin, CS6 mediates the attachment of the bacteria to the small intestinal epithelium, which is the essential initial step for toxin delivery and the subsequent development of watery diarrhea. CS6 is among the most prevalent colonization factors globally, making it a cornerstone target for multivalent ETEC vaccines and passive immunotherapies. Current drug development efforts focus on inducing or providing antibodies that block CS6-mediated adherence, thereby preventing infection. Despite its importance, CS6 often exhibits lower immunogenicity compared to other fimbrial antigens, posing a challenge for vaccine design. Targeting this antigen is vital for addressing ETEC-related morbidity in travelers and children in resource-limited settings.
Inhibition of bacterial adherence to intestinal epithelial cells
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coli surface antigen 6 (CS6) (CS6).